ACM
HQL

Armbruster Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Armbruster Capital Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-591
Closed -$13K – 275
2017
Q3 		$13K Buy
+591
New +$12.6K 0.01% 185

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
CAN
Claraphi Advisory Network Aliso Viejo, United States $251M AUM 9.29% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Armbruster Capital Management's HQL Position: Q4 2017 in Review

Armbruster Capital Management sold out of abrdn Life Sciences Investors (HQL) in Q4 2017, closing a stake of 591 shares — an estimated $13K sold.

Armbruster Capital Management first reported a position in HQL in Q3 2017 and held it in 1 quarter. The position peaked at $13K in Q3 2017. 55 funds tracked by Wall St. Rank hold HQL as of Q4 2017.

  • Armbruster Capital Management reported no remaining abrdn Life Sciences Investors position as of Q4 2017 after selling out during the quarter.
  • Armbruster Capital Management sold 591 abrdn Life Sciences Investors shares in Q4 2017, an estimated $13K.
  • Armbruster Capital Management first reported a position in abrdn Life Sciences Investors in Q3 2017 and held it in 1 quarter.
  • Armbruster Capital Management's abrdn Life Sciences Investors position peaked at $13K in Q3 2017.
  • 55 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2017.

Based on Armbruster Capital Management's 13F filing for Q4 2017, filed 2 Feb 2018.